Marges de sécurité Doit-on prendre en compte certains critères (cliniques, radiologiques, biologiques) particuliers?
Author:
Guinebretière J.-M.
Reference25 articles.
1. Schnitt SJ, Connolly JL, Harris JR, Hellman S, Cohen RB (1984) Pathologic predictors of early local recurrence in Stage I and II breast cancer treated by primary radiation therapy. Cancer 53: 1049–1057
2. Koscielny S, Tubiana M (1999) The link between local recurrence and distant metastases in human breast cancer. Int J Radiat Oncol Biol Phys 43: 11–24
3. Cutuli B, Cohen-Solal-Le Nir C, De Lafontan B et al. (2001) Ductal carcinoma in situ of the breast results of conservative and radical treatments in 716 patients. Eur J Cancer 37: 2365–2372
4. Fisher B, Dignam J, Wolmark N et al. (1999) Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 353: 1993–2000
5. Houghton J, George WD, Cuzick J, Duggan C, Fentiman IS, Spittle M (2003) Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial. Lancet 362: 95–102